Table 1: Inclusion and exclusion criteria.
Inclusion criteria |
• Known CNV secondary to AMD or PCV as demonstrated by fluorescein and ICG angiography. • Prior treatment with at least 4 injections of anti-VEGF agents (bevacizumab or ranibizumab) in the past 6 months and persistent intraretinal or subretinal fluid, or both, on spectral-domain optical coherence tomography during this period. • Pigment epithelial detachments were included as long as there was associated subretinal fluid or intra retinal oedema. • BCVA between 35 and 90 ETDRS chart letters. |
Exclusion criteria |
• Uncontrolled IOP of more than 25 mmHg. • Current vitreous haemorrhage or inflammation. • Prior vitrectomy or any intraocular surgery within 2 months of study commencement. • Anti-VEGF therapy within the previous 30 days; photodynamic therapy within the previous 90 days. • If the OCT was dry at any time during the 3 months before switching to aflibercept (to allow the inclusion of previously responsive tachyphylactic eyes). • More than 2 prior photodynamic therapy treatments. • Presence of significant subretinal fibrosis, tubulation, cystic degeneration or atrophy. • Significant corneal or lenticular opacities. • Myocardial infarction, transient ischemic attack, or cerebrovascular accident within the previous 90 days. |